Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...

Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government ...

The drugs identified for negotiation in the second round include: Ozempic, Wegovy and other GPL-inhibitors are in high demand in the U.S. Due to that demand, Medicare covering them for diabetes ...

This will be a “pivotal year,” one expert says, for GLP-1 drugs, which are massively disrupting the benefits landscape.

As a weight management doctor, Mollie Cecil has seen first-hand how the latest weight-loss drugs help her patients. She knows from personal experience, too. After a year on one medication, the West ...

The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was ...

If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS ...

Some workers are willing to trade vacation days or go back to the office in exchange for weight-loss drug coverage by their ...

U.S. President Donald Trump is set to meet with top pharmaceutical executives on Thursday, a White House official confirmed.

Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching hundreds of dollars per prescription. The poll found that about half of Americans ...

(Reuters) - U.S. President Donald Trump will meet on Thursday with chief executives from major drugmakers, a White House ...